{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:26Z","timestamp":1791254786078,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"C2N Diagnostics, LLC","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"name":"C2N Diagnostics, LLC","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}]},{"name":"C2N Diagnostics, LLC","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}]},{"name":"Gerald and Henrietta Rauenhorst Foundation (GHR)","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"name":"Gerald and Henrietta Rauenhorst Foundation (GHR)","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}]},{"name":"Gerald and Henrietta Rauenhorst Foundation (GHR)","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}]},{"name":"Alzheimer\u2019s Drug Discovery Foundation","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"name":"Alzheimer\u2019s Drug Discovery Foundation","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}]},{"name":"Alzheimer\u2019s Drug Discovery Foundation","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}]},{"name":"BrightFocus","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"name":"BrightFocus","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}]},{"name":"BrightFocus","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}]},{"name":"NIH","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"name":"NIH","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}]},{"name":"NIH","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Objective: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. Methods: The Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey (NCT06025877) study evaluated the clinical utility of the PrecivityAD2\u2122 blood test in a prospective, single cohort of 203 patients presenting with symptoms of Alzheimer\u2019s disease (AD) or other causes of cognitive decline across 12 memory specialists. The PrecivityAD2 blood test (C2N Diagnostics, St. Louis, MO) combines the plasma A\u03b242\/A\u03b240 ratio and the p-tau217\/np-tau217 ratio (%p-tau217) measurements in a statistical algorithm to yield an Amyloid Probability Score 2 (APS2) that informs on the likelihood of brain amyloid plaques. After receiving the BBM test results, clinicians completed surveys on management strategies for each patient. Results: Patients had a median age of 74, 53% were female, and 28% were traditionally under-represented in Black, Hispanic, and Asian groups. The composite primary endpoint, defined as a change in AD diagnostic certainty, drug therapy, or additional brain amyloid evaluation pre- and post-BBM testing, was 75% (p &lt; 0.0001 versus the pre-specified threshold of 20% clinically meaningful change). Anti-AD medication orders decreased among negative APS2 patients and increased among positive APS2 patients (p &lt; 0.0001). Additional brain amyloid testing decreased among negative APS2 patients (p &lt; 0.0001). Conclusions: This blood biomarker test can help memory specialists guide patients to anti-AD therapies as well as rule out AD to allow for other diagnostic considerations.<\/jats:p>","DOI":"10.3390\/diagnostics15020167","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:31:31Z","timestamp":1736767891000},"page":"167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Utility of an Alzheimer\u2019s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-4415","authenticated-orcid":false,"given":"Mark","family":"Monane","sequence":"first","affiliation":[{"name":"C<sub>2<\/sub>N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius M.","family":"Maraganore","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Carlile","sequence":"additional","affiliation":[{"name":"Palmetto Primary Care Physicians, Summerville, SC 29486, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-3839","authenticated-orcid":false,"given":"David A.","family":"Merrill","sequence":"additional","affiliation":[{"name":"Pacific Neuroscience Institute, Santa Monica, CA 90404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-5605","authenticated-orcid":false,"given":"Darren R.","family":"Gitelman","sequence":"additional","affiliation":[{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Sharlin","sequence":"additional","affiliation":[{"name":"Sharlin Health and Neurology, Ozark, MO 65721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawren A.","family":"VandeVrede","sequence":"additional","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, San Francisco, CA 94103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi K.","family":"George","sequence":"additional","affiliation":[{"name":"JWM Neurology, Indianapolis, IN 46256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Wang","sequence":"additional","affiliation":[{"name":"Stat4ward, Pittsburgh, PA 15238, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-8249","authenticated-orcid":false,"given":"Tim","family":"West","sequence":"additional","affiliation":[{"name":"C<sub>2<\/sub>N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Jacobs","sequence":"additional","affiliation":[{"name":"C<sub>2<\/sub>N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Verghese","sequence":"additional","affiliation":[{"name":"C<sub>2<\/sub>N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"C<sub>2<\/sub>N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"ref_1","unstructured":"FRED (2024, November 19). Federal Reserve Bank of St. Louis. Available online: https:\/\/fred.stlouisfed.org\/series\/LNU00024230."},{"key":"ref_2","first-page":"e12497","article-title":"Estimating prevalence of early symptomatic Alzheimer\u2019s disease in the United States","volume":"15","author":"Spargo","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.mayocp.2014.06.019","article-title":"Mild cognitive impairment and mild dementia: A clinical perspective","volume":"89","author":"Knopman","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2023). 2023 Alzheimer\u2019s Disease Facts and Figures. Alzheimer\u2019s Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2967\/jnumed.123.265766","article-title":"Quantitative brain amyloid PET","volume":"65","author":"Jagust","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacr.2012.05.005","article-title":"Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer","volume":"9","author":"Onega","year":"2012","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/alz.12372","article-title":"State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer\u2019s disease","volume":"18","author":"Hampel","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1002\/alz.14150","article-title":"Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_11","unstructured":"(2024, October 19). Global CEOi Initiative on Alzheimer\u2019s Disease. Available online: www.alzbiomarkerhub.org."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.medj.2024.08.004","article-title":"Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease","volume":"5","author":"Hu","year":"2024","journal-title":"Med"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults with Cognitive Impairment","volume":"5","author":"Hu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51863","article-title":"A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment","volume":"10","author":"Monane","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Eastwood, S.M., Meyer, M.R., Kirmess, K.M., Wente-Roth, T.L., Irvin, F., Holubasch, M.S., Verghese, P.B., West, T., Braunstein, J.B., and Yarasheski, K.E. (2024). PrecivityAD2\u2122 Blood Test: Analytical Validation of an LC-MS\/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-\u03b242\/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics, 14.","DOI":"10.20944\/preprints202406.1343.v1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.14283\/jpad.2024.67","article-title":"Optimising Alzheimer\u2019s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment","volume":"11","author":"Aye","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_20","unstructured":"(2024, October 27). Equator Network. Available online: https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jakobsen, J.C., Gluud, C., Winkel, P., Lange, T., and Wetterslev, J. (2014). The thresholds for statistical and clinical significance\u2014A five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-34"},{"key":"ref_22","unstructured":"Cox, D.R., and Snell, E.J. (1989). Analysis of Binary Data, Chapman & Hall. [2nd ed.]."},{"key":"ref_23","unstructured":"Rosner, B. (1986). Hypothesis testing: Categorical data. Fundamentals of Biostatistics, PWS Publishers."},{"key":"ref_24","unstructured":"(2024, September 18). The R Foundation. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: Considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s43587-024-00675-3","article-title":"A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer\u2019s disease","volume":"4","author":"Hansson","year":"2024","journal-title":"Nat. Aging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.14283\/jpad.2022.85","article-title":"Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU\/US CTAD Task Force","volume":"9","author":"Angioni","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014Recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_30","first-page":"e12081","article-title":"Blood-based biomarkers for Alzheimer\u2019s pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11673-018-9844-y","article-title":"Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer\u2019s Disease","volume":"15","author":"Vanderschaeghe","year":"2018","journal-title":"J. Bioeth. Inq."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s disease facts and figures","volume":"18","author":"Gaugler","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3934\/publichealth.2022047","article-title":"The physician\u2019s Alzheimer\u2019s disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer\u2019s disease and related dementia","volume":"9","author":"Reiss","year":"2022","journal-title":"AIMS Public. Health"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gresenz, C.R., Mitchell, J.M., Rodriguez, B., Turner, R.S., and van der Klaauw, W. (2024, December 25). The Financial Consequences of Undiagnosed Memory Disorders; Federal Reserve Bank of New York Staff Reports. Available online: https:\/\/www.newyorkfed.org\/research\/staff_reports\/sr1106.html.","DOI":"10.59576\/sr.1106"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.14283\/jpad.2024.83","article-title":"Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer\u2019s Disease. Are We Ready for the New Era?","volume":"11","author":"Kalsi","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nijakowski, K., Owecki, W., Jankowski, J., and Surdacka, A. (2024). Salivary Biomarkers for Alzheimer\u2019s Disease: A Systematic Review with Meta-Analysis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021168"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1467-9566.13713","article-title":"Detecting value(s): Digital biomarkers for Alzheimer\u2019s disease and the valuation of new diagnostic technologies","volume":"46","author":"Costa","year":"2024","journal-title":"Sociol. Health Illn."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Singh, S.G., Das, D., Barman, U., and Saikia, M.J. (2024). Early Alzheimer\u2019s Disease Detection: A Review of Machine Learning Techniques for Forecasting Transition from Mild Cognitive Impairment. Diagnostics, 14.","DOI":"10.3390\/diagnostics14161759"},{"key":"ref_41","unstructured":"(2024, October 01). Center for Medicare and Medicaid Services, Available online: https:\/\/www.cms.gov\/files\/document\/cms-framework-health-equity-2022.pdf."},{"key":"ref_42","unstructured":"(2024, September 15). Office of the Assistant Secretary for Planning and Evaluation, Available online: https:\/\/aspe.hhs.gov\/reports\/racial-ethnic-disparities-alzheimers-disease-literature-review-0."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2022-329530","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: A systematic review and meta-analysis","volume":"94","author":"Hazan","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000478007","article-title":"Effectiveness of Florbetapir PET Imaging in Changing Patient Management","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of Amyloid Positron Emission Tomography with Subsequent Change in Clinical Management Among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/pop.2023.0309","article-title":"Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment","volume":"27","author":"Canestaro","year":"2024","journal-title":"Popul. Health Manag."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103911","DOI":"10.1016\/j.drudis.2024.103911","article-title":"Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer\u2019s disease diagnosis","volume":"29","author":"Noda","year":"2024","journal-title":"Drug Discov. Today"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:02Z","timestamp":1759919282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15020167"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15020167","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}